Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (221-230 of 868) with videos related to

Pageof 87
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasoneSachin S Saboo, Fiona Fennessy, Lina Benajiba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactionsConstantine S Mitsiades, Nicholas S Mitsiades, Nikhil C Munshi, et al.
Oral Oncology|August 22, 2008
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patientsStephen T Sonis, Brynmor A Watkins, Gregory D Lyng, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Expert Review of Hematology|February 17, 2011
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myelomaJacob P Laubach, Robert L Schlossman, Constantine S Mitsiades, et al.
Cancer Research|October 16, 2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cellsDharminder Chauhan, Guilan Li, Reshma Shringarpure, et al.
Cancer Metastasis Reviews|December 3, 2017
The proteasome and proteasome inhibitors in multiple myelomaSara Gandolfi, Jacob P Laubach, Teru Hideshima, et al.
Blood|October 24, 2002
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieuTeru Hideshima, Masaharu Akiyama, Toshiaki Hayashi, et al.
International Journal of Oncology|February 1, 2014
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cellsHiromasa Hideshima, Yasuhiro Yoshida, Hiroshi Ikeda, et al.
Journal of Cellular Biochemistry|June 5, 2007
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironmentConstantine S Mitsiades, Nicholas S Mitsiades, Paul G Richardson, et al.
Pageof 87

Showing results (221-230 of 868) with videos related to

Sort By:
Pageof 87
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasoneSachin S Saboo, Fiona Fennessy, Lina Benajiba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactionsConstantine S Mitsiades, Nicholas S Mitsiades, Nikhil C Munshi, et al.
Oral Oncology|August 22, 2008
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patientsStephen T Sonis, Brynmor A Watkins, Gregory D Lyng, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Expert Review of Hematology|February 17, 2011
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myelomaJacob P Laubach, Robert L Schlossman, Constantine S Mitsiades, et al.
Cancer Research|October 16, 2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cellsDharminder Chauhan, Guilan Li, Reshma Shringarpure, et al.
Cancer Metastasis Reviews|December 3, 2017
The proteasome and proteasome inhibitors in multiple myelomaSara Gandolfi, Jacob P Laubach, Teru Hideshima, et al.
Blood|October 24, 2002
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieuTeru Hideshima, Masaharu Akiyama, Toshiaki Hayashi, et al.
International Journal of Oncology|February 1, 2014
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cellsHiromasa Hideshima, Yasuhiro Yoshida, Hiroshi Ikeda, et al.
Journal of Cellular Biochemistry|June 5, 2007
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironmentConstantine S Mitsiades, Nicholas S Mitsiades, Paul G Richardson, et al.
Pageof 87